Search
eosinophilic asthma
Laboratory:
- complete blood count
- eosinophil count > 150-300/uL
Management:
- glucocorticoids for asthma exacerbations
- IL5-inhibitors
- mepolizumab may diminish exacerbations & the need for glucocorticoids [1]
- benralizumab (Fasenra) [4]
- reslizumab (Cinqair)
- omalizumab (Xolair) [3]
Notes:
- editorialist notes that asthma exacerbations decreased by 50% with placebo in one study suggesting that frequent monitoring of patients may lead to better control without the need for expensive biologic therapy [1]
Related
eosinophilic bronchitis
eosinophilic pneumonia; Andrews syndrome; pulmonary eosinophilia
General
asthma
pulmonary infiltrates with eosinophilia (PIE) syndrome
References
- Ortega HG et al.
Mepolizumab treatment in patients with severe eosinophilic
asthma.
N Engl J Med 2014 Sep 8;
PMID: 25199059
- Bel EH et al.
Oral glucocorticoid-sparing effect of mepolizumab in
eosinophilic asthma.
N Engl J Med 2014 Sep 8
PMID: 25199060
- Nair P
Anti-interleukin-5 monoclonal antibody to treat severe
eosinophilic asthma.
N Engl J Med 2014 Sep 8
PMID: 25197762
- Castro M, Corren J, Pavord ID et al
Dupilumab Efficacy and Safety in Moderate-to-Severe
Uncontrolled Asthma.
N Engl J Med. May 21, 2018
PMID: 29782217 Free full text
https://www.nejm.org/doi/full/10.1056/NEJMoa1804092
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
- From The Medical Letter on Drugs and Therapeutics
Benralizumab (Fasenra) for Severe Eosinophilic Asthma.
JAMA. 2018;319(14):1501-1502
PMID: 29634828
https://jamanetwork.com/journals/jama/fullarticle/2678013